This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.





NUCALA is indicated for the add-on maintenance treatment of patients 6 years and older with severe asthma with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

proven protection

53% reduction in exacerbations vs placebo1*

real-world evidence

Associated with:

69% reduction in exacerbations from baseline2

34% of patients eliminated maintenance OCS use2

Results are descriptive

long-term results

The only anti-interleukin 5 (IL-5) with a


open-label study that evaluated safety and efficacy3

  •   REALITI-A2:  Interim analysis of a prospective observational cohort study of 368 patients. Exacerbations: 4.63/year at baseline vs 1.43/year at 12 months. OCS: 34% (43/125) during Weeks 53-56 of patients on maintenance OCS at baseline. Results are descriptive. Study Limitations: May not reflect final results. Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. Limitations important when interpreting results: lack of comparator arm; differences in patient populations and data collection vs randomized controlled trials.
  •   *MENSA1: 32-week placebo-controlled study in 576 patients. NUCALA: 0.83/year, placebo: 1.74/year; P<0.001.
  •   ‡Following the optimization phase in a controlled OCS reduction trial, 14% (10/69) of patients treated with NUCALA vs 8% (5/66) treated with placebo eliminated daily OCS use while maintaining asthma control (See Clinical Efficacy).5


  1. Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198-1207.
  2. Data on file, GSK.
  3. Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742-1751.
  4. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651-659.
  5. Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189-1197.